Induction of functional empty class I major histocompatibility complex glycoproteins by photoactivated 8-methoxypsoralen

Journal of Investigative Dermatology

Volumn 107, Issue 6, 1996, Pages 887-890

  Imaeda, Suguru ^a,c   Felli, Andrea ^b   Schmitt, Iris ^b   Chimenti, Sergio ^b   Edelson, Richard L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c Department of Dermatology ^*  (United States)

Author keywords

Cold induction; Peptide; Tumor specific; Vaccine

Indexed keywords

ACTIN; GLYCOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOXSALEN; PEPTIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; T LYMPHOCYTE; ULTRAVIOLET A RADIATION;

EID: 0029856322     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12331193     Document Type: Article

References (33)

1. Aichele P, Brduscha-Riem K, Zinkernagel RM, Hengartner H, Pircher H: T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 182:261-266, 1995
2. Allen H, Wraith D, Pala P, Askonas B, Flavell RA: Domain interactions of H-2 class I antigens alter cytotoxic T-cell recognition sites. Nature 309:279-281, 1984
3. Attaya M, Jameson S, Martinez CK, Hermel E, Aldrich C, Forman J, Lindahl KF, Bevan MJ, Monaco JJ: Ham-2 corrects the class I antigen-processing defect in RMA-S cells. Nature 355:647-649, 1992
4. Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S: Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181:619-629, 1995
5. Baskar S, Nabavi N, Glimcher LH, Ostrand-Rosenberg S: Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J Immunother 14:209-215, 1993a
6. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH: Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90:5687-5690, 1993b
7. Bellone M, Iezzi G, Manfredi AA, Protti MP, Dellabona P, Casorati G, Rugarli C: In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J Immunol 24:2691-2698, 1994
8. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102, 1992
9. De Bruijn MLH, Schumacher TNM, Nieland JD, Ploegh HL, Kast WM, Melief CJM: Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur J Immunol 21:2963-2970, 1991
10. Fahnestock ML, Tamir I, Narhi L, Bjorkman PJ: Thermal stability comparison of purified empty and peptide-filled forms of a class I MHC molecule. Science 258:1658-1662, 1992
11. Gabathuler R, Reid G, Kolaitis G, Driscoll J, Jefferies WA: Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 180:1415-1425, 1994
12. Gervois N, Guilloux Y, Diez E, Jotereau F: Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 183:2403-2407, 1996
13. Hammerling GJ, Klar D, Katzav S, Segal S, Feldman M, Wallich R, Hammerling A: Manipulation of metastasis and tumour growth by transfection with histocompatibility class I genes. J Immunogenet 13:153-157, 1986
14. b antigens determined with monoclonal antibodies and H-2 mutant mice. Proc Natl Acad Sci USA 79:4737-4741, 1982
15. Hui K, Grosveld F, Festenstein H: Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311:750-752, 1984
16. Jones B, Janeway CA Jr.: Cooperative interaction of B lymphocytes with antigen-specific helper T lymphocytes in MHC restricted. Nature 292:547-549, 1981
17. Karre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678, 1986
18. Kast WM, Roux L, Curren J, Blom HJJ, Voordouw AC, Meloen RH, Kolakovsky D, Melief CJM: Proc Natl Acad Sci USA 88:283, 1991
19. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462, 1994
20. Ljunggren H-G, Karre K: Host resistance directed selectively against H-2-deficient lymphoma variants. J Exp Med 162:1745-1759, 1985
21. 2-microglobulin observed in cells with increased sensitivity to NK cell lysis. J Immunol 142:2911-2917, 1989
22. Ljunggren H-G, Stam NJ, Ohlen C, Neefjes JJ, Hoglund P, Heemels M-T, Bastin J, Schumacher TNM, Townsend A, Karre K, Ploegh HL: Empty MHC class I molecules come out in the cold. Nature 346:476-480, 1990
23. Nieland JD, Kruisbeek AM: A T cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70. Int Immunol 7:1827-1838, 1995
24. Ortiz-Navarrete V, Hammerling GJ: Surface appearance and instability of empty H-2 class I molecules under physiological conditions. Proc Natl Acad Sci USA 88:3594-3597, 1991
25. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR: Identification of human cancers deficient in antigen processing. J Exp Med 177:265-272, 1993
26. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA, Marincola FM: Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55:3149-3157, 1995
27. Rock KL, Gramm C, Benacerraf B: Low temperature and peptides favor the formation of class I heterodimers on RMA-S cells at the cell surface. Proc Natl Acad Sci USA 88:4200-4204, 1991
28. Schumacher TNM, De Bruijn MLH, Vernie LN, Kast WM, Melief CJM, Neefjes JJ, Ploegh HL: Peptide selection by MHC class I molecules. Nature 350:703-706, 1991
29. Schumacher TNM, Heemels M-T, Neefjes JJ, Kast WM, Melief CJM, Ploegh HL: Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 62:563-567, 1990
30. Sijts AJAM, De Bruijn MLH, Nieland JD, Kast WM, Melief CJM: Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor cell line. Eur J Immunol 22:1639-1642, 1992
31. Townsend S, Allison J: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368-370, 1993
32. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M: Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301-305, 1985
33. White HD, Robbins MD, Green WR: Mechanism of escape of endogenous murine leukemia virus emv-14 from recognition by anti-AKR/Gross virus cytolytic T lymphocytes. J Virol 64:2608-2619, 1990